PS
PeptideScholar

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

KPV

DLimited Data

Alpha-MSH C-terminal tripeptide · 3 amino acids

Not FDA ApprovedWADA Banned

KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (alpha-MSH). Research suggests potent anti-inflammatory activity without the pigmentation effects of the parent hormone.

Mechanism of Action

Enters cells and inhibits NF-kB nuclear translocation, reducing inflammatory cytokine production (IL-1beta, IL-6, TNF-alpha). Acts intracellularly rather than through melanocortin receptors.

Benefits

  • Potent anti-inflammatory effects in cell studies
  • Reduced colitis severity in animal models
  • No melanocyte stimulation or tanning effects
  • Antimicrobial properties against S. aureus
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

KPV — Dosing in Published Research

Reported Routes: Oral, Subcutaneous injection, Topical
Research dosing not established for humans. Animal studies typically used 100-400 mcg doses. Explored in both injectable and oral formats.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Very limited human data
  • Unknown systemic safety profile
  • Potential GI effects with oral use
  • Unknown drug interactions

Considering Peptide Research?

KPV is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Learn About Finding a Provider
Always Consult a Professional

Research & Evidence

In VitroJournal of Biological Chemistry, 2004

Anti-inflammatory effects of alpha-MSH C-terminal peptide KPV

KPV inhibited NF-kB activation and reduced pro-inflammatory cytokine production through intracellular peptide transporter PepT1

PMID: 15246227
AnimalGastroenterology, 2006

KPV reduces experimental colitis

Oral KPV attenuated DSS-induced colitis in mice by inhibiting NF-kB-driven inflammation in colonic epithelial cells

PMID: 16697918

Compare KPV With

KPV vs BPC-157
KPV vs GHK-Cu

References

  1. 1. Anti-inflammatory effects of alpha-MSH C-terminal peptide KPV. Journal of Biological Chemistry, 2004. “KPV inhibited NF-kB activation and reduced pro-inflammatory cytokine production through intracellular peptide transporter PepT1” [PMID: 15246227]
  2. 2. KPV reduces experimental colitis. Gastroenterology, 2006. “Oral KPV attenuated DSS-induced colitis in mice by inhibiting NF-kB-driven inflammation in colonic epithelial cells” [PMID: 16697918]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get Peptide Research Updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.